---
title: "Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Other product development or post-marketing obligations required by the FDA"
description: "Formulary evidence on Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Other product development or post-marketing obligations required by the FDA. Topics: Data required by the FDA for inclusion in the planned submission and Paediatric investigation plan agreed by the European Medicines Agency. 2 evidence topics quoted from 2 sources."
canonical: "https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description/other-product-development-or-post-marketing-obligations-required-by-the-fda"
published: "2026-11-15T20:23:41-05:00"
modified: "2026-11-15T20:23:41-05:00"
---

# Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Other product development or post-marketing obligations required by the FDA

<a id="heading-2.2.2.5"></a>

## 2.2.2.5 Other Product Development or Post-marketing Obligations Required by the FDA

<a id="topic-2.2.2.5-1"></a>

### FDA post-marketing obligations

No evidence found.

<a id="topic-2.2.2.5-2"></a>

### Data required by the FDA for inclusion in the planned submission

> “A minimum of three months of ASPIRE safety data will be included in the planned BLA submission, while efficacy in the 2 to <6-year-old population will be extrapolated from data collected in the REVEAL pivotal trial.”
> “The FDA also endorsed our proposed Process Performance Qualification, or PPQ, campaign strategy to support process validation for the BLA submission, including the stability data package, the potency assay strategy, and the execution of BLA-enabling PPQ lots using the commercial manufacturing process.”

Source: [Taysha Gene Therapies third quarter 2026 Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456949/tsha-20260930.htm)

<a id="topic-2.2.2.5-3"></a>

### Paediatric investigation plan agreed by the European Medicines Agency

> “A paediatric investigation plan for adeno-associated viral vector serotype 9 containing the human MECP2 gene, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.”
> “A deferral for adeno-associated viral vector serotype 9 containing the human MECP2 gene, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.”
> “Open-label, randomized, 2-part study including a dose-escalation (Part A) and dose expansion (Part B) to evaluate the safety, efficacy, and durability of a single intrathecal dose of TSHA-102 in female children from 2 to less than 9 years of age with Rett syndrome with a documented MECP2 loss-of-function gene mutation.”

Source: [EMA paediatric investigation plan decision (2025)](https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000232894-ema-decision-14-april-2025-agreement-paediatric-investigation-plan-granting-deferral-adeno-associated-viral-vector-serotype-9-containing-human-mecp2-gene_en.pdf-0)

## Related pages
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Terms and abbreviations](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations.md)
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Product information and disease description](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Clinical evidence](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Economic information and modeling report](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: References](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references.md)
